25.03
-1.31(-4.97%)
Currency In USD
Address
280 East Grand Avenue
South San Francisco, CA 94080
United States of America
Phone
(650) 231-6625
Website
Sector
Healthcare
Industry
Biotechnology
Employees
168
First IPO Date
February 22, 2021
| Name | Title | Pay | Year Born |
| Martin Babler | President, Chief Executive Officer & Chairman | 912,638 | 1965 |
| Roy C. Hardiman | Chief Business & Strategy Officer | 619,841 | 1960 |
| David Goldstein | Chief Scientific Officer | 651,368 | 1966 |
| Jorn Drappa | Chief Medical Officer & Head of Research and Development | 0 | 1965 |
| John R. Schroer | Chief Financial Officer | 0 | 1965 |
| Kolbot By | Senior VP & Head of Technical Operations | 0 | N/A |
| Mark Bradley | Chief Development Officer | 0 | 1965 |
| Philip Nunn | Senior VP of Pharmacology & Project Team Leader | 0 | N/A |
| Claire Langrish | Senior VP & Head of Immunology and Translational Science | 0 | N/A |
| Sanam Pangali | Chief Legal Officer & Corporate Secretary | 0 | N/A |
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.